Nutriband Inc
$ 3.52
3.23%
11 Jun - close price
- Market Cap 41,451,900 USD
- Current Price $ 3.52
- High / Low $ 3.53 / 3.41
- Stock P/E N/A
- Book Value 0.55
- EPS -2.58
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.69 %
- ROE -1.26 %
- 52 Week High 11.68
- 52 Week Low 3.21
About
Nutriband Inc. develops a portfolio of transdermal pharmaceuticals. The company is headquartered in Orlando, Florida.
Analyst Target Price
$15.00
Quarterly Earnings
| Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | Jul 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-06-05 | 2026-04-29 | 2025-12-16 | 2025-09-09 | 2025-05-30 | 2025-04-28 | 2024-12-03 | 2024-09-03 | 2024-05-31 | 2024-04-30 | 2023-12-12 | 2023-09-11 |
| Reported EPS | -0.0796 | -0.04 | -0.32 | -2.12 | -0.5 | -0.51 | -0.1227 | -0.1542 | -0.2072 | -0.2295 | -0.2247 | -0.1059 |
| Estimated EPS | -1.89 | -1.89 | -2.13 | -0.17 | -0.12 | -0.12 | None | None | None | None | -0.06 | -0.07 |
| Surprise | 1.8104 | 1.85 | 1.81 | -1.95 | -0.38 | -0.39 | 0 | 0 | 0 | 0 | -0.1647 | -0.0359 |
| Surprise Percentage | 95.7884% | 97.8836% | 84.9765% | -1147.0588% | -316.6667% | -325% | None% | None% | None% | None% | -274.5% | -51.2857% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NTRB
2026-06-11 20:39:55
NutriBand Inc. (NTRB) filed its quarterly earnings report (10-Q) for the period ended April 30, 2026, showing a net loss of $1,241,956, or $0.10 per share. The company generated $433,399 in revenue, primarily from its Pocono Pharmaceuticals segment, with no revenue from 4P Therapeutics due to a shift in focus. Nutriband continues to develop its AVERSA™ abuse-deterrent transdermal technology, particularly for AVERSA Fentanyl, and maintains sufficient liquidity with $4,006,184 in cash and cash equivalents.
2026-06-07 06:40:21
This article provides access to the number of shareholders for Nutriband Inc. (NASDAQ: NTRBW) through TradingView's platform. It mentions that market data is provided by ICE Data Services, reference data by FactSet, and SEC filings by Quartr. The core content linked is about the ownership structure of Nutriband Inc.
2026-05-29 18:39:16
Nutriband, Inc. stock has fallen to a new 52-week low of $3.28, reflecting significant financial challenges in the Pharmaceuticals & Biotechnology sector. The company reported a 42.03% decline in net sales and a 47.4% net profit loss, resulting in a negative return on equity of 121.64%. This performance has led to a -43.48% return over the past year, underperforming the S&P 500.
2026-05-29 08:39:16
Nutriband Inc.'s equity buyback program, which was originally announced on September 18, 2024, has now expired. The company officially ended its plan on January 31, 2026. This announcement highlights the conclusion of their share repurchase initiative.
2026-05-29 02:08:59
Nutriband, Inc. (NTRB) has hit a new 52-week low of $3.38, with its stock declining 41.25% over the past year. The microcap pharmaceutical company faces challenges including a negative return on equity, concerning operating cash flow of -$5.64 million, and rising raw material costs. These financial hurdles highlight the difficulties microcap stocks encounter in the current market.
2026-05-20 00:10:27
Nutriband's subsidiary, Active Intelligence, will be featuring its expanding line of wellness, recovery, and performance-focused consumer products at the ECRM conference in June 2026. The company intends to showcase its existing AI Tape and unveil new products such as AI Performance Tape, AI Energy Patches, and AI Sleep, aiming to secure more retail partnerships and distribution opportunities. Nutriband Inc. specializes in transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch.
